Skip To Main Content
Brian Gazaille on Muck Rack

Brian Gazaille

Verified
(He/Him)
Eugene
As seen in: BioProcess International Magazine
Covers:  Biopharmaceutical development and manufacturing, antibodies, mAbs, vaccines, mRNA, viral vectors, cell and gene therapies

Get in touch with Brian

Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Consistency Is Key: Managing Complexity When Scaling Out Adherent-Cell Cultures

|
By Brian Gazaille Verified, Tom Bongiorno
| BioProcess International Magazine Verified
Adherent-cell culture remains a cornerstone of biological research and commercial biopharmaceutical manufacturing. For viral vaccines, production in anchorage-dependent cell lines has largely surmounted egg-based methods because of advantages for scalability and product quality (see Figure 1 for a sample workflow). Therapies based on mesenchymal stem cells generally depend on expansion steps in adherent cultures. And applications continue to proliferate.
Open in Who Shared Issue with article?

eBook: Bioconjugates — Extending the Logic of Targeted Drug Delivery

|
By Brian Gazaille Verified, Sung Lee
| BioProcess International Magazine Verified
After a few decades of occasional commercial successes tempered by clinical setbacks, antibody–drug conjugates (ADCs) finally have hit their stride. Between 2020 and 2025, regulatory agencies approved eight such products — more than had received approval in the 20 years preceding. Having cleared initial hurdles attributable to molecular instability and immature linker technologies, drug companies are bringing many candidate ADCs into clinical studies.
Open in Who Shared Issue with article?

Fujifilm Cellular Dynamics Boosts Stem-Cell Capacity at New Madison Site

|
By Brian Gazaille Verified
| BioProcess International Magazine Verified
Fujifilm Cellular Dynamics (FCDI), a global manufacturer of human induced pluripotent stem cell (iPSCs) and service provider for stem-cell applications, has launched a new facility in its hometown of Madison, Wisconsin. Bearing some of the fruits from a US$200 million strategic investment by Fujifilm Corporation in December 2023, the 175,000-ft2 building is designed to integrate cutting-edge capabilities for cell culture and process development as well as a gene editing center of excellence.
Open in Who Shared View Duplicates (35) Issue with article?
See all 93 articles